Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Humacyte, Inc.
Unprofitable (net margin -2003.6%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Humacyte, Inc. shows $2.04M in FY2025 revenue, a -2003.6% net margin, and -1313.4% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001818382, latest 10-Q filed 2026-05-13) · EODHD · rules-based read · as of 6/18/2026, 7:08:27 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $2.04M |
| Gross profit | — | — | — | — | — |
| Operating income | -$81.2M | -$84.6M | -$100M | -$114M | -$108M |
| Net income | -$26.5M | -$12.0M | -$111M | -$149M | -$40.8M |
| Diluted EPS | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
| Net margin | — | — | — | — | -2003.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median